Pfizer Inc. (NYSE: PFE) has disclosed positive top-line results from the Phase 3 study (B7471026) of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) when administered together with the Pfizer-BioNTech COVID-19 vaccine. The study included 570 adults in the United States aged 65 or older.  The trial was designed to evaluate the safety and immunogenicity of PREVNAR 20 when administered along with the Pfizer-BioNTech COVID-19 vaccine, or with a placebo.   Notably, PREVNAR 20 is Pfizer’s next-generation pneumococcal conjugate vaccine consisting of capsular polysaccharide conjugates for the 13 serotypes. In addition, the vaccine contains capsular polysaccharide conjugates for seven additional serotypes that have been associated with high fatality rates.
https://www.tipranks.com/news/pfizer-reveals-positive-results-from-phase-3-study-of-prevnar-20?utm_source=advfn.com&utm_medium=referral